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Huntington’s disease (HD) is an incurable neurodegenerative disorder caused by a CAG
repeat expansion in exon 1 of the Huntingtin (HTT) gene. Recently, induced pluripotent
stem cell (iPSC) lines carrying atypical and aggressive (CAG60+) HD variants have been
generated and exhibit disparate molecular pathologies. Here we investigate two human
embryonic stem cell (hESC) lines carrying CAG37 and CAG51 typical late-onset repeat
expansions in comparison to wildtype control lines during undifferentiated states and
throughout forebrain neuronal differentiation. Pluripotent HD lines demonstrate growth,
viability, pluripotent gene expression, mitochondrial activity and forebrain specification
that is indistinguishable from control lines. Expression profiles of crucial genes known
to be dysregulated in HD remain unperturbed in the presence of mutant protein and
throughout differentiation; however, elevated glutamate-evoked responses were observed
in HD CAG51 neurons. These findings suggest typical late-onset HD mutations do not
alter pluripotent parameters or the capacity to generate forebrain neurons, but that such
progeny may recapitulate hallmarks observed in established HD model systems. Such HD
models will help further our understanding of the cascade of pathological events leading
to disease onset and progression, while simultaneously facilitating the identification of
candidate HD therapeutics.
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INTRODUCTION
Huntington’s disease (HD) is an autosomal dominant neurode-
generative disorder caused by an expanded CAG repeat tract in
exon 1 of the HTT gene (Group, 1993). Disease alleles (CAG>35)
exhibit an age-dependent penetrance, with the lowest disease
range (CAG36−39) associated with a later onset (McNeil et al.,
1997). CAG40+ alleles are associated with full penetrance, while
larger expansions (CAG60+) result in juvenile or infantile onset
(Andrew et al., 1993; Squitieri et al., 2006). Substantial correlation
of∼50% exists between CAG repeat length and age of onset, with
secondary contributions from known and unknown genetic and
environmental factors (Andrew et al., 1993; Wexler et al., 2004).
HD affects approximately 1 in 10,000 individuals worldwide, with
onset of disease usually in the fourth or fifth decade of life. HD
culminates in death 15–20 years after persistent, irreversible and
debilitating clinical symptoms (Naarding et al., 2001). To date,
there is no cure for HD and consequently, there is an unmet
clinical need for more effective therapeutics.
TheHTT gene comprises 67 exons and encodes a ubiquitously
expressed protein of approximately 350 kDa called Huntingtin
(HTT). HTT plays a critical role in early embryogenesis with
homozygous HTT null mouse embryos exhibiting incomplete
neural development and lethality at embryonic day 8.5 and 10.5
of gestation (Zeitlin et al., 1995). HTT has been extensively stud-
ied in relation to its interacting partners, sub-cellular localization
and effects on gene expression, and acts in a variety of cellular sys-
tems (Zuccato et al., 2010). The clinical symptoms of HD seen in
patients can largely be classified as either neural, such as behavior
and cognitive alterations, or motor, such as involuntary move-
ments and abnormalities of voluntary movements. Underlying
neurodegeneration is most prominent within the GABAergic
medium spiny neurons of the striatum although widespread neu-
ronal loss occurs with disease progression (Graveland et al., 1985;
Vonsattel et al., 1985).
Understanding the molecular nature of HD is critical to the
development of novel and efficacious therapies. Numerous ani-
mal models such as the R6/2 transgenic mouse (Mangiarini
et al., 1996) together with post mortem patient tissues have
proven valuable resources for identifying and elucidating major
CNS cellular mechanisms and hallmarks that contribute to
HD pathology; these are comprehensively reviewed in Zuccato
et al. (2010) and include transcriptional dysregulation, CAG
repeat expansion, excitotoxic stress, autophagy-lysosomal, and
proteasome-ubiquitin system perturbation, anterograde and
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retrograde transport interference, mitochondrial dysfunction and
cholesterol biosynthesis alteration.
The hierarchical relationship between the disparate mecha-
nisms/hallmarks and their degree of individual contribution to
the overall HD phenotype still remains uncertain. New human
HD models such as pluripotent stem cells (PSCs) may provide
an alternative system to shed light on this etiological question.
Studies investigating hPSC lines, specifically human embryonic
stem cell (hESC) lines, carrying pathogenic CAG repeat muta-
tions have provided limited data in relation to the consequences
of disease allele expression (Niclis et al., 2009; Bradley et al.,
2011; Seriola et al., 2011). More recently, mouse and human
induced pluripotent stem cell (iPSC) lines have been analysed
for the appearance of HD hallmarks (Camnasio et al., 2012;
Castiglioni et al., 2012; HDIPSCC, 2012; Jeon et al., 2012) and
several phenotypes have been observed, including transcriptional
dysregulation, CAG repeat instability, mutant HTT aggregates,
cholesterol biosynthesis perturbation, lysosomal dysfunction and
neuronal vulnerability. However, phenotypes reported from the
various HD iPSC studies differ significantly and rarely correlate,
for example CAG repeat instability is seen in human but not
R6/2 iPSCs. A further caveat is that the HD iPSC lines studied
to date either carry rare homozygous HD mutations or alleles
with egregious repeat tracts (CAG60−180) indicative of juvenile
and infantile onset and may represent atypical disease scenarios.
Limited studies assess the appearance of HD phenotypes
in hPSC lines with clinically relevant trinucleotide expansions
(CAG35−60) that correlate with late ages of onset. To this end, we
have extended an earlier study byNiclis et al. (2009) using twoHD
hESC lines SI-187 (CAG51/19) and SI-186 (CAG37/15) that were
generated from embryos identified with pre-implantation genetic
detection (PGD). Here we show that the HD hESC lines are
indistinguishable from control hESCs with respect to pluripotent
characteristics, mitochondrial function, forebrain neural differ-
entiation capabilities, relevant cellular phenotypes and with no
evidence of a dysregulated transcriptome in key HTT associ-
ated genes. However, the larger of the two CAG repeat cell lines
showed an altered responsiveness to the neurotransmitter glu-
tamate. Overall, these results are informative for establishing a
human neuronal cellular model of HD.
MATERIALS ANDMETHODS
CULTURE AND NEURAL DIFFERENTIATION OF hESC LINES
Two HD hESC lines SI-186 (CAG37/15) and SI-187 (CAG51/19)
(Niclis et al., 2009) as well as two wildtype control hESC lines,
HES3 and H9 (Thomson et al., 1998; Reubinoff et al., 2000) were
used. All hESC lines were screened for karyotypic abnormalities
using Geisma staining and found tomaintain euploid 46XX kary-
otypes (data not shown). All four hESC lines were grown as bulk
cultures on γ-irradiated mouse embryonic fibroblasts (MEFs)
according to previously described conditions (Costa et al., 2008);
briefly, cells were grown in DMEM/ F-12, supplemented with
0.1mM β-mercaptoethanol, 1% non-essential amino acids, 1%
Glutamax, 25U/ml penicillin, 25U/ml streptomycin, and 20%
knockout serum replacement (all Invitrogen).
hESC neural differentiation was performed as previ-
ously described (Song et al., 2011a). Briefly, ∼3000 hESCs
were distributed to each well of a round-bottom ultra-low
attachment 96-well plate (Corning) containing 100μl of
Differentiation Medium (Neurobasal A, 5% ITS-X, 2.5%
Penicillin/Streptomycin, 5% Glutamax, 5% B27 and 5% N2;
Invitrogen). From d0–d21 cells were grown as neurospheres
at 37◦C in 5% CO2 in air, with 0.125% polyvinyl alcohol and
10μM Roh-Associated Coil Kinase (ROCK) inhibitor Y-27632
at d0–4. From d0–d21 media was supplemented with 20 ng/ml
epidermal growth factor (EGF) and 20 ng/ml fibroblast growth
factor (FGFb) (R&D Systems), and 100 ng/ml of Noggin (R&D
Systems) from d0–8. Neurospheres were passaged at d14 by
manual sectioning in half. To promote neuronal differentiation
neurospheres were plated at d21 in Differentiation Medium
onto 24-well plates (BD Biosciences) coated with 20μg/ml
poly-D-lysine and 20μg/ml laminin (Invitrogen) in the absence
of growth factors and media changed every 4 days for up to
24 days.
FLOW CYTOMETRY
Cells were harvested using TrypLE Select (Invitrogen), passed
through a 70μmfilter and 1 × 105 cells stained with various anti-
bodies listed in Table 1. Samples were analysed using a BD Canto
II flow cytometer with data analyses performed using GateLogic.
All samples were gated to assess only single cells as determined
by forward scatter area vs. height channels and live cells as
determined by negative DAPI selection. Background fluorescence
was subtracted using unlabeled cells. A total of 50,000 events
(∼40,000 live cells) were recorded, compensations were per-
formed using single label antibody controls; positive gates were
designated on concentration-matched isotype control antibodies.
GENOTYPING
Genotyping was performed as previously described (Niclis et al.,
2009). Briefly, HU3 and HU4 primers (Sermon et al., 1998)
were used to amplify the CAG repeat expansion region in
exon 1 of HTT. The HU4 sense primer was labeled with
6-carboxyfluorescein (6-FAM) and sizing of amplicons per-
formed with an ABI Prism 3100 DNA sequencer coupled with
GeneScan Software according to previously described methods
(Cram et al., 2000). The number of CAG repeats was accurately
calculated to ±1 bp from GeneScan sized F-PCR products, using
Table 1 | Antibodies and dilutions utilized for flow cytometry and
immunocytochemistry.
Antibody target Species Conjugate Dilution Company
CD9 Mouse FITC 1:30 BD
TRA-1-60 Mouse APC 1:25 BD
FORSE-1 Mouse N/A 1:1000 DSHB
CD56 Mouse PerCPcy5.5 1:50 BD
β-III-TUBULIN Mouse N/A 1:500 Millipore
Huntingtin Rabbit N/A 1:100 Millipore
SOX2 Goat N/A 1:200 ABcam
OTX2 Rabbit N/A 1:1000 Millipore
GABA Rabbit N/A 1:500 Millipore
FOXG1 Rabbit N/A 1:50 ABCam
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the formula: CAG repeat number = (size of PCR product – size
of non-CAG repeat region)/3.
IMMUNOCYTOCHEMISTRY
Neurospheres were collected at d10 or 21 and fixed for 15min at
room temperature with 4% paraformaldehyde, cryoprotected in
sucrose (20% w/v in 0.1M PBS) and embedded in OCT com-
pound (Tissue–Tek) before serial sectioning (6 × 10μm thick
sections) on a cryostat (Leica). Neuronal cultures were fixed at
d35 or 45 for 15min at room temperature with 4% paraformalde-
hyde, permeabilized with 1% Triton X-100 (Ameresco), blocked
using 10% normal donkey serum (Invitrogen) and incubated
with primary antibodies described in Table 1 at 4◦C overnight.
Species-specific AlexaFluor (Invitrogen) or Dyelight (Jackson
Laboratories) 488 and 555 secondary antibodies (all 1:200) were
added for 2 h at room temperature and then counterstained
with 0.1μg/ml DAPI (SIGMA). Coverslips were mounted onto
glass slides using Fluorescent Mounting Media (DAKO). Bound
fluorescence was detected using an Olympus BX51 microscope
coupled to the ULH100HG fluorescence system. Images were
captured using a DP70 camera.
CELL GROWTH AND VIABILITY ASSAYS
Duplicate MEF coated T25 culture flasks were seeded with 1 ×
106 hESCs for each line. Cells were harvested at 24 and 72 h.
FACS analysis of DAPI, CD9, and TRA-1-60 staining was used
to distinguish live hESCs (DAPI–/CD9+/TRA1–60+) and MEFs
(DAPI–/CD9–/TRA1–60–). Doubling rates were calculated based
on hESC and live cells only, according to the following formu-
lae: [Log2(β/α)]/2; α = 24 h count and β = 72 h count. Viability
assays were performed similarly on hESCs 24 h after passage but
with DAPI live and dead cell gating performed by FACS after
CD9 and TRA-1–60 gating. Neurosphere growth rates were deter-
mined by measuring area sizes using Adobe Photoshop CS5, the
average value for 12 neurospheres equated a single replicate, with
three averaged values analysed at each time point for each line.
Data values at d21 were doubled to account for passaging in half
of spheres at d14. Data was statistically analysed with PRISM,
using a One-Way ANOVA with a Kruskal–Wallis Test and Dunn’s
post test. Means were graphed with the SEM and a p-value (∗) of
< 0.05 considered significantly different.
NEURONAL FUNCTIONAL ANALYSIS
Neurons were cultured as described above. For intracellular Ca2+
[(Ca2+)i] imaging, neurons were loaded with Fluo4-AM (2μM,
for 45min at 37◦C, as previously described (Watmuff et al., 2012).
Media was then replaced with HEPES buffer (of composition,
mM, NaCl 145; MgSO4 1; KCl 5; glucose 10; CaCl2 2.5; HEPES
10; pH 7.4) containing bovine serum albumin (0.3% w:v) and
placed on a heated (37◦C) stage. Neurons were viewed using a
Nikon A1R confocal microscope and excited with a 488 nm laser,
emission was recorded at 525/50 nm at two image frames per
second. After 2min of baseline recording glutamate (30μM) or
vehicle was added to each well and imaging continued for 90 s
as previously described (Raye et al., 2007; Khaira et al., 2011;
Watmuff et al., 2012). After this time KCl (30mM) was added to
each well and imaging continued for a further 60 s. For analysis,
background emission light was subtracted from analysis regions
defined within each cell body and emission intensity within each
region calculated using Nikon Elements software. The maximal
elevation of intracellular [Ca2+]i in response to vehicle or gluta-
mate is expressed as the net fraction of the KCl-induced maximal
increase in [Ca2+]i.
QUANTITATIVE REAL-TIME PCR
Total RNA was extracted from ∼ 1 × 106 cells using the
commercially available RNeasy Mini Kit (Qiagen) as per
the manufacturer’s instructions and treated with RNase-Free
DNase (Qiagen). RNA was quantitated using a ND-1000
Spectrophotometer (NanoDrop Technologies). Purified RNA
(0.4–2μg) was reverse transcribed to single stranded cDNA
with SuperScript III reverse transcriptase using the First Strand
Synthesis System Kit (Invitrogen) and treated with RNase H to
remove contaminating RNA.
cDNA products were subjected to qRT-PCR of selected
genes (Table 2) using TaqMan® Universal PCR Master Mix
and the inventoried TaqMan® Gene Expression Assay Kit
(Applied Biosystems) according to manufacturer’s recommenda-
tions. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was
used for normalization of RNA input, two independent reactions
were prepared for each sample. Reaction plates were run on the
7500 Real Time PCR System (Applied Biosystems) at the fol-
lowing thermocycler conditions: stage 1, 50◦C for 2min; stage
2, 95◦C for 10min and stage 3, 40 cycles of 95◦C for 15 s and
60◦C for 1min. The relative quantification (RQ) of gene expres-
sion in each sample was analysed using SDS Software version 1.3
(Applied Biosystems). The Ct value for each sample wasmeasured
in duplicate and the average normalized against the endogenous
control GAPDH to determine the Ct value. The Ct values
were then standardized against the calibrator’s Ct (wildtype
HES3 line) to yield the Ct. The RQ was then calculated as
2−Ct. Statistical analysis for qRT-PCR data was performed
using GraphPad Prism with a one-way ANOVA analysis of each
gene at each specific time point. A Kruskal–Wallis test was per-
formed on the non-matched, non-parametric data. The p-value
was set to <0.05 and a Dunn’s post-test performed with RQ data
from three culture replicates plotted as a mean and scale bars
denoting the mean ± SEM.
Table 2 | TaqMan gene expression assay details used for qRT-PCR.
Gene symbol Amplicon Gene bank number Assay ID
length (bp)
GAPDH 93 NM_002046.3 Hs99999905_m1
HTT 66 NM_002111.6 Hs00918134_m1
PGC1a 74 NM_013261.3 Hs01016719_m1
DRP1 88 NM_005690.3 Hs00247147_m1
BDNF 116 NM_170733.3 Hs00380947_m1
DRD2 64 NM_000795.3 Hs00241436_m1
PENK 56 NM_001135690.1 Hs00175049_m1
SREBP1 90 NM_001005291.2 Hs01088691_m1
β-III-TUBULIN 82 N/A Hs00964967_g1
All primers were purchased from Applied Biosystems.
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WESTERN BLOTTING
1 × 106 cells were lysed in 500μl of Cell Lysis Buffer (Cell
Signaling) and protein concentrations determined using a BCA
assay (Pierce, Thermo Scientific). Protein samples (10μg) in 1×
SDS sample buffer containing 10% β-mercaptoethanol were elec-
trophoresed on 4–12% NuPAGE gels (Invitrogen). Proteins were
transferred to immobilon PVDF transfer membranes (Millipore),
blocked in TBS-T containing 5% non-fat dry milk powder and
then immunoblotted with either monoclonal antibody 1HU-
4C8 (Millipore, 1:2000) specific for epitopes within amino acids
181–810 on wildtype and mutant HTT or monoclonal antibody
5TF1-1C2 (Millipore, 1:5000) which has a high avidity for long
polyglutamine epitopes (>15 polyglutamine residues). A sec-
ondary anti-mouse HRP antibody (Calbiochem) in combination
with an ECL kit was finally used to illuminate HTT protein.
JC-1 MITOCHONDRIAL STAINING
JC-1 a cationic dye that undergoes a fluorescence emission shift
from green (529 nm) to red (590 nm) upon accumulation in the
mitochondrial matrix (Simeonova et al., 2004), was employed
to measure changes in the mitochondrial membrane potential
(MMP). Undifferentiated hESCs (1× 106) prepared from bulk
cultures were incubated in media containing 2μM of JC-1 for
30min, washed twice in PBS and then analysed using a BD FACS
Canto II flow cytometer 488 nm excitation and emission detec-
tion dually from both FITC and PE channels. Compensations
were performed with hESC specific CD9 and EpCAM antibodies,
conjugated to FITC and PE respectively. Data analysis was con-
ducted using FACS Diva software (BD).
RESULTS
CHARACTERIZATION OF PLURIPOTENT HD hESC LINES
HD and control hESC lines were originally derived as colony cul-
tures that intrinsically comprise significant heterogeneity with
differential degrees of pluripotency and differentiation capaci-
ties across a gradient of isolatable sub-fractions (Laslett et al.,
2007; Hough et al., 2009; Kolle et al., 2009). To eliminate this
stochasticity, HD hESC lines were adapted to an enzymatically
passaged bulk culture system to provide homogenous cultures
amenable to stringent molecular and functional comparative
evaluations. Of note, adaptation rates of HD lines were com-
mensurate with controls, requiring ∼3–5 passages, and produced
morphologically identical bulk culture monolayers of hESCs with
low cytoplasmic-to-nuclear ratios (Figures 1A,B). Robust homo-
geneity was achieved with hESC bulk culture conditions, evi-
denced by a tightly clustered population of TRA-1-60+/CD9+
pluripotent cells and an absence of single positive cells indi-
cating that the hESCs were maintained in a pluripotent state
(Figure 1C). Both HD hESC lines exhibited FACS profiles with
pluripotent markers similar to control lines verifying stable undif-
ferentiated states (Figure 1C). Further, no significant differences
in cell growth rates (doublings/48 h) were observed between HD
and control hESC lines (SI-187 2.24, SI-186 2.8, HES3 2.36, and
H9 2.52, p > 0.05; Figure 1H) or cell viability during enzymatic
FIGURE 1 | Characterization of pluripotent HD hESC lines demonstrates
identical characteristics to control lines. (A,B) Brightfield morphology of
hESC bulk cultures. (C) Flow cytometry analysis of hESCs seen as a
TRA-1-60+/CD9+ population; feeder MEFs are a distinct CD9–/TRA-1-60-
sub-population. (D) FL-PCR representation of HD genotypes. (E) qRT-PCR of
HTT mRNA expression levels. (F) Western blot of an N-terminal epitope
antibody on the 350 kDa HTT protein. (G) Western blot of hESC lines
immunoprobed with the IC2 monoclonal antibody. (H) Growth rates of hESC
lines (One-Way ANOVA, n = 3, p ≥ 0.05) and (I) cell viability comparisons
(One-Way ANOVA, n = 3, p ≥ 0.05).
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passaging (SI-187 79.3%, SI-186 78.0%, HES3 84.7%, and H9
87.3%, p > 0.05; Figure 1I).
Analysis of FL-PCR products confirmed correct CAG repeat
genotypes for HD lines SI-187 (CAG51/19) and SI-186 (CAG37/15)
and control lines HES3 (CAG15/15) and H9 (CAG23/15)
(Figure 1D). qRT-PCR using primers specific for conserved
sequences on both wildtype and mutant alleles confirmed HTT
mRNA was expressed at similar levels in HD and control hESC
lines (Figure 1E). Western blot analysis using a polyclonal anti-
body reactive to an N-terminal epitope on the 350 kDa HTT
protein (Figure 1F) confirmed HTT protein expression in all four
hESC lines. Further immunoprobing using the IC2 monoclonal
antibody that specifically reacts with long polyglutamine epitopes
>15–20 residues (Trottier et al., 1995) detected a ∼350 kDa band
exclusively within SI-187 and SI-186 cells confirming mutant
HTT expression in both HD lines (Figure 1G).
NEURAL DIFFERENTIATION IS UNPERTURBED BY AN EXPANDED
CAG TRACT
HD neurodegeneration emerges within the forebrain and pro-
gresses to whole-brain atrophy. Differentiation of HD hESC
lines to a regionally relevant forebrain phenotype was achieved
using the spin aggregation neurosphere system we have previ-
ously reported (Song et al., 2011a). Seeding 3000 hESCs per
well resulted in morphologically similar neurospheres within 24 h
and throughout the neurosphere differentiation stage between
HD and control lines (Figure 2A). Neural growth rates were
equivalent between HD and control lines indicating the presence
of mHTT does not interfere with neural precursor division and
differentiation (p > 0.05; Figure 2B).
Quantitative flow cytometric assessment throughout neuro-
sphere stages demonstrated highly analogous expression profiles
across HD and control lines. All lines progress early to a neu-
ral fate and near total expression (>90%) of the pan-neural
marker CD56 is observed by d21 (Figure 2C). Neural differ-
entiation exhibited an anterior identity with >50% of cells
expressing the forebrain surface antigen FORSE-1 (Figure 2C).
The forebrain population was confirmed as neural in charac-
ter with >90% of the FORSE-1+ population co-staining with
CD56 by d21 (Figure 2D), and all FORSE-1+ cells separat-
ing from minor CD9+ fractions (Figure 2E). All hESCs rapidly
exit a pluripotent state with low levels of the hESC marker
CD9 d10 which falls to ∼2% by d21 (Figure 2E). Intriguingly,
a delay in CD9 downregulation is observed in the fully pen-
etrant SI-187 line at d10, although by d21 CD9 expression is
consistent across all lines (Figure 2E). Overall, these findings
suggest that pathogenic HD mutations do not perturb neural
progenitor generation, expansion or specification to an anterior
identity.
Control and HDneurospheres exhibited equivalent progenitor
phenotypes at d10 (Figures 3A–H). Strong expression of the mul-
tipotent neural stem cell transcription factor SOX2 was observed
in control (85.8%) andHD (88.2%) cells equally (Figure 3D, data
not significant p = 0.05). This was concomitant with a rostral
FIGURE 2 | Neural progenitor lineage specification and expansion is
consistent between HD and control neurospheres. (A) Brightfield time
course representations throughout neurosphere differentiation stages (B).
Neurosphere growth rate analysis across all HD and control lines (One-Way
ANOVA, n = 3, p ≥ 0.05) from an initial 3000 cell seeding density. Flow
cytometry quantification of antigens CD9, CD56, and FORSE-1 at differentiation
days, d10 and d21 showing (C) absolute single antibody expression levels and
(D)co-expressionscatterplots forCD56andFORSE-1and (E)CD9andFORSE-1.
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FIGURE 3 | Equivalent neurosphere neural progenitor gene expression
and forebrain specification from HD and control cryosectioned
immunostained neurospheres. Neurospheres at d10 of differentiation
from HD line SI-187 (A–C) and control line H9 (E–G), demonstrate robust
expression of the telencephalic marker OTX2 (green) and similarly the neural
progenitor marker SOX2 (red). Merged images demonstrate co-expression of
OTX2 and SOX2 and quantitative evaluation shows no significant difference
between control and HD neurospheres (D, H, paired t-test, n = 4 p ≥ 0.05).
Neurospheres at d21 of differentiation from HD line SI-187 (I–K) and control
line H9 (M–O) show extensive expression of the forebrain transcription factor
FOXG1 (green) and nascent expression of the cytoskeletal marker
β-III-TUBULIN (red) which predominates within FOXG1 expressing regions,
with no quantitative differences between control and HD neurospheres
(L, paired t-test, n = 8 p ≥ 0.05).
fate seen by the robust expression of the telencephalic marker
OTX2 in comparable proportions between control (88.0%) and
HD (92.4%) cells (Figure 3H, data not significant p = 0.05), and
by co-localization of both proteins (Figures 3C,G). Importantly,
continued differentiation to d21 facilitated robust expression of
the forebrain specific transcription factor FOXG1 within the
majority of neurosphere cells in both control and HD sections
(Figures 3I–O). Expression levels of FOXG1 were not signifi-
cantly different between control (71.9%) and HD (79.4%) neuro-
spheres (Figure 3L, p = 0.05). Limited numbers of neuronal cells
were seen at the end of neurosphere culture, detected by β-III-
TUBULIN expression (Figures 3J,N). FOXG1 expressing regions
preferentially co-localize with β-III-TUBULIN expression indi-
cating maturation of anterior cells to a post-mitotic neuronal fate
(Figures 3K,O).
Subsequent to neurosphere plating on extracellular matri-
ces, neuronal differentiation disseminated throughout cultures
in control (Figure 4A) and HD neurons (Figure 4D) as shown
by cytoskeletal β-III-TUBULIN immunostaining. Quantitative
validation was made of these observations during late neuro-
spheres (d21) and neuronal (d35) differentiation stages by β-
III-TUBULIN transcript expression comparisons (Figure 4G).
Antibody staining against an N-terminal HTT epitope revealed
cytoplasmic and nuclear protein localization (Figures 4B,E)
and specifically preferential nuclear reactivity within the nuclei
of neurons with no discernable differences between control
(Figure 4C) and HD neurons (Figure 4F). Further, quantita-
tive HTT transcript expression levels were equal across all HD
and control lines during neural precursor and neuronal differ-
entiation stages (Figure 4H). Crucially, neuronal differentiation
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FIGURE 4 | Unperturbed neuronal differentiation in HD lines. Neuronal
differentiation of (A–C) control HES3 and (D–F) HD SI-187 cells at d35, with
immunocytochemical staining demonstrating (A,D) β-III-TUBULIN expression
(green) and (B,E) HTT expression (red). (C,F) Merged images reveal HTT
localization within neuronal cells. (G) Neuronal differentiation qRT-PCR
comparisons of β-iii-TUBULIN expression during late neurosphere (d21) and
neuronal (d35) stages. (H) HTT transcript expression across HD and control
lines during mid-neurosphere (d14) and neuronal (d35) stages.
of anterior neurosphere cells culminated in robust detection of
the neurotransmitter GABA, which was observed in equal pro-
portions throughout the elaborate neuronal networks produced
from control HES3 (Figures 5A–C) and H9 (Figures 5D–F) as
well as HD SI-186 (Figures 5G–I) and SI-187 (Figures 5J–L)
cell lines. Co-staining for β-III-TUBULIN and GABA demon-
strate the majority of neuronal cells possess a GABAergic identity
(Figures 5C,F,I,L).
FUNCTIONAL RESPONSES OF NEURONAL CULTURES
Neurons derived from this culture protocol were compared to
their respective vehicle control wells with all four hESC derived
neuronal cultures responding to glutamate (30μM) with a sig-
nificant elevations of [Ca2+]i, Figure 5M for a typical raw
trace after background subtraction and Figure 5N for a typical
response profile (One-Way ANOVA with post-hoc Tukey test).
Interestingly, neurons derived from the fully penetrant SI-187 cell
line responded to glutamate with a significantly greater elevation
of [Ca2+]i than neurons from the wildtype HES3 andH9 lines, or
the partially penetrant SI-186 line (p < 0.05, One-Way ANOVA
with post-hoc Tukey test, Figure 5O).
TRANSCRIPTIONAL ANALYSIS OF MUTANT HTT MODULATED GENES
Recent studies of HD human embryonic carcinoma cells (hECCs)
and iPSC lines demonstrate in vitro gene expression alterations
(Gaughwin et al., 2011; Castiglioni et al., 2012). Whether similar
transcriptome disruptions are evident in late-onset CAG length
hESC lines remains uncertain. Expression levels of critical tran-
scripts identified in previous studies and those with direct paths
from mHTT expression to gene disruption were assessed by
qRT-PCR in undifferentiated HD and control lines (day 0),
within neurospheres derivatives at day 14 and at neuronal pro-
moting stages (day 35) (Figure 6). Selected for assessment were
neural-specific genes Brain-Derived Neurotrophic Factor (BDNF;
Zuccato and Cattaneo, 2007, 2009), dopamine receptor D2
(DRD2) and proenkephalin (PENK) (Luthi-Carter et al., 2000;
Dunah et al., 2002; Hodges et al., 2006). Also assessed were the
cholesterol biosynthesis transcripts 7-Dehydrocholesterol reduc-
tase (7-DHCR) and sterol regulatory element-binding protein 1
(SREBP1) (Valenza et al., 2005; Valenza and Cattaneo, 2011), as
well as transcription factor EB (TFEB) a master regulator of lyso-
somal biogenesis (Sardiello et al., 2009; Settembre et al., 2011;
Camnasio et al., 2012). At day 0 and 14 significant downregu-
lation of PENK mRNA expression was observed in SI-187 cells
compared to HES3 cells (p < 0.05; Figure 6C) and SREBP1 was
significantly up-regulated in SI-187 compared to HES3 at day 0
(p < 0.05; Figure 6D). Nevertheless, significant gene expression
changes in PENK and SREBP1mRNA of HD SI-187 cells were not
corroborated when compared to the second control line H9 (p >
0.05), suggesting these discrepancies are a consequence of inter-
line variation as opposed to CAG repeat length. mRNA expression
levels of the remaining genes BDNF, DRD2, 7-DHCR7, and TFEB
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FIGURE 5 | Efficient differentiation to GABAergic neurotransmitter
subtypes and glutamate response perturbations in HD neurons.
(B,E,H,K) Neuronal differentiation extended to d45 generated elaborate
networks shown by β-III-TUBULIN (red) immunostaining. GABAergic
neurons detected by GABA immunostaining (green) were equivalently
detected throughout neuronal cultures from control lines (A) HES3 and
(D) H9, as well as HD lines (G) SI-186 and (J) SI-187. (C,F,I,L) Merged
images illustrating co-localization between GABA and β-III-TUBULIN.
(M) Example of a typical raw trace after background subtraction measured
in arbitrary units of fluorescence intensity and (N) a typical neuronal Ca2+
response profile, left x-axis arrows indicate glutamate (30μM) addition and
right x-axis arrows KCl (30mM) addition. (O) Intracellular [Ca2+]i levels in
response to vehicle and glutamate (30μM) addition for all control and HD
neuronal cultures.
were similar across HD and control lines at days 0, 14, and 35
(p > 0.05) (Figures 6A,B,E,F).
ASSESSMENT OF MITOCHONDRIAL GENE EXPRESSION AND
FUNCTION
Mitochondrial dysfunction comprises a robust hallmark of
HD pathology, measurable by cellular dysregulation of key
transcripts, deficits in mitochondrial energy capacities, and
fusion/fission events (Cantuti-Castelvetri et al., 2005; Cui et al.,
2006; Knott et al., 2008; Song et al., 2011b). qRT-PCR analysis
of mitochondrial genes PGC-1α, a master regulator of mitochon-
drial biogenesis and energy metabolism and DRP1, a regulator
of mitochondrial fusion and fission showed no consistent differ-
ences in transcript levels between both control and HD hESCs
or neural differentiated derivatives (Figures 7A,B respectively).
Intriguingly, significant (p < 0.05) downregulation of SI-187
PGC-1α mRNA levels compared to H9 samples were observed at
d14 and a similar yet non-significant trend was seen with SI-186
at d14 and both HD lines at d21 compared to wildtype controls
(Figure 6B). Mitochondrial functional JC-1 assays that directly
measure MMP found all hESC lines demonstrated similar pop-
ulations of cells exhibiting dual red and green fluorescence (HES3
95%, H9 68%, SI-186 86%, and SI-187 81%; Figure 7C), indica-
tive of an active MMP. Remaining green fluorescent cells from
each line represented a sub-population of cells with less active
mitochondria.
DISCUSSION
Human PSCs provide a unique window to investigate the rami-
fications of mutant HTT within the intracellular milieu from the
earliest stages of human development until the specification of
relevant neuronal subtypes. This study assesses two HD hESCs
carrying expanded CAG repeat lengths representative of those
harbored by individuals with archetypal late clinical onset. For
the first time, we report detailed quantitative evaluations of the
pluripotent properties and neural differentiation capabilities of
these HD hESC lines using two wildtype control hESC lines as
biological comparisons. Our studies of undifferentiated hESCs
show expanded CAG repeat tracts have no adverse effects on stem
cell parameters that were assessed, such as viability, mitochondrial
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FIGURE 6 | qRT-PCR transcriptional analysis of relevant HD related
transcripts modulated by mutant HTT. Relative transcript quantification
for all four lines are normalized to the control HES3 line and were
evaluated across a differentiation time course at the undifferentiated
stage (d0), mid-neurosphere stage (d14) and neuronal differentiation
stage (d35). Transcripts are assessed for (A) BDNF, (B) DRD2, (C)
PENK, (D) SREPB1, (E) 7-DHCR, and (F) TFEB. One-Way ANOVA,
∗p < 0.05.
function, proliferation, and pluripotency markers. These find-
ings are in agreement with recent pluripotent HD studies that
observe no disturbance to similar parameters (Gaughwin et al.,
2011; Camnasio et al., 2012; Castiglioni et al., 2012; HDIPSCC,
2012; Jeon et al., 2012).
Further, we demonstrate for the first time that neural differ-
entiation of hESCs with HD mutations is equivalent to wildtype
controls. Expression of neural markers CD56 and SOX2 and
equivalent growth rates of neurospheres show unaltered differ-
entiation in the presence of mutant HTT. Transient lag in the
downregulation of the pluripotency marker CD9 was however,
observed in one HD line, and corroborates findings of HD hECCs
(Gaughwin et al., 2011). Crucially anterior specification assessed
by key markers OTX2, FOXG1, and FORSE-1 were equivalent
across all lines irrespective of CAG repeat length, and further
extended differentiation produced consistent neuronal networks
with similar acquisition of GABAergic identities upon in vitro
maturation. These findings are consistent withmouse and human
HD iPSC studies (Camnasio et al., 2012; Castiglioni et al., 2012;
HDIPSCC, 2012).
HD patients and animal models are characterized by cor-
ticostriatal synaptic dysfunction and profligate excitotoxicity
(Raymond, 2003; Estrada Sanchez et al., 2008). A major compo-
nent of this pathological mechanism is glutamate receptor hyper-
sensitivity on postsynaptic GABAergic striatal neurons. Striatal
neurons receive essential glutamate signaling from cortical axons
and mutant HTT is directly responsible for excessive Ca2+ influx
downstream of glutamate stimulation, as seen in YAC128 (Tang
et al., 2005) and R6/2 (Cepeda et al., 2001) transgenic models.
Mutant HTT aberrantly binds endoplasmic reticulum InsP3R1
receptors that are critical for Ca2+ release. This in turn increases
the responsiveness of InsP3R1 receptors to upstream glutamate
receptor agonists and induces abnormal Ca2+ release (Tang et al.,
2003, 2005).
In our studies we identified increased neuronal Ca2+ elevation
in the fully penetrant HD line SI-187 upon glutamate stimulation
that suggests late-onset HD hESCs are be capable of recapitu-
lating some neuronal pathologies that characterize established
HD model systems. Detectable alterations in Ca2+ glutamate
responses are not unexpected with evidence of this phenotype
in GABAergic neurons from pre-onset HD mice (Cepeda et al.,
2001; Laforet et al., 2001) and even within neurons isolated
as early as post-natal day 0-1 (Zeron et al., 2004). Together,
these findings suggest increased Ca2+ responses may occur in
early human stages of HD and thus represent a potentially valu-
able therapeutic target. The absence of such observations in
the partially penetrant SI-186 line may correspond with the
lesser pathological intensity of mutant proteins comprising 35–39
polyglutamine tracts and prolonged neuronal culture may be
necessary to manifest this functional state.
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FIGURE 7 | Assessment of mitochondrial gene expression and
function. Relative transcript quantification for all four lines are
normalized to the control HES3 line for mitochondrial genes (A) DRP1
and (B) PGC-1α at the undifferentiated (d0), neurosphere (d14) and
neuronal (d35) stages of differentiation. (C) Mitochondrial functional
JC-1 assay quantifying activity of the mitochondrial membrane
potential (MMP) between control and HD hESCs. One-Way ANOVA,
∗p < 0.05.
Extensive mutant HTT dysregulation of the cellular transcrip-
tomes is a dominant hallmark seen in post-mortem brain tissue
from HD patients and across animal models, reportedly affecting
∼1–2% of total cellular transcripts (Cha, 2000; Luthi-Carter et al.,
2002a,b; Hodges et al., 2006). Transcript alteration has emerged as
a focal point across HD pluripotent cell studies of aggressive HD
subclasses, though little consensus appears to date. Exemplifying
this are contrary observations of BDNF transcript stability and
downregulation compared to controls in generated neural cul-
tures (Gaughwin et al., 2011; Castiglioni et al., 2012; HDIPSCC,
2012). This contradiction is surprising considering clear evi-
dence from model systems of the process by which mutant HTT
instigates reduced BDNF expression via nuclear translocation of
the transcriptional repressor REST (Zuccato and Cattaneo, 2007;
Zuccato et al., 2007). Our study found BDNF is not altered
in neural and neuronal derivatives of HD hESCs carrying typi-
cal late-onset ranges, suggesting BDNF may not be dysregulated
unless significant pathology has progressed.
None of the remaining transcripts analysed in the HD hESC
lines were significantly changed at either pluripotent or neural
differentiated time points when compared to both control hESC
lines. SREBP1, a cholesterol biosynthesis regulator, was signifi-
cantly upregulated in pluripotent SI-187 cells compared to one
control and approached significance to the second control line;
a finding consistent with overt cholesterol biosynthesis disrup-
tion in HD models (Valenza et al., 2007a,b), patients (Markianos
et al., 2008) and undifferentiated HD iPSC lines (Castiglioni
et al., 2012). Further, there was a transient downregulation of the
mitochondrial gene PGC-1α at d14 in SI-187 neural derivatives
which continued to d21 although the trend was not statistically
significant at the latter time-point. To corroborate this find-
ing, we undertook functional studies of MMP activity, which
is reduced when PGC-1α is down-regulated. In both undiffer-
entiated cells and in d14 neurospheres from SI-186 and SI-187
(data not shown) we found no evidence of altered MMP. Together
these findings in conjunction with those of other pluripotent sys-
tems imply transcript disturbances in this class of in vitromodels
may be a phenomenon that predominates in lines equivalent to
juvenile and infantile disease subclasses, warranting array based
studies to scrutinize cellular transcriptomes across a range of lines
carrying different CAG repeat lengths.
In summary we have provided detailed characterization of HD
hESCs and also those that harbor typical CAG repeat expan-
sions. We demonstrate for the first time that pluripotent dynam-
ics and forebrain neuronal differentiation are unhindered but
that glutamate signaling perturbations indicative of Huntington’s
pathology are observable subsequent to extended in vitro cul-
ture and cellular acquisition of a forebrain GABAergic neuron
identity. These late-onset hESC lines demonstrate the potential
of such model systems to provide a platform to interrogate dis-
ease mechanisms and hallmarks. Advances describing the efficient
generation of DARPP32+ medium spiny neurons provide an
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opportunity for probing HD etiology within a more relevant cell
type (Ma et al., 2012) and could be coupled with proteasomal
inhibition or oxidative stress to exacerbate disease phenotypes as
demonstrated recently (HDIPSCC, 2012; Jeon et al., 2012).
Emergent studies of HD iPSCs describe lines that possess atyp-
ical alleles representative of rare juvenile/infantile (CAG60+) or
homozygous subclasses that are poorly studied in human patients
(Camnasio et al., 2012; Castiglioni et al., 2012; HDIPSCC, 2012;
Jeon et al., 2012). The observation of some HD specific pheno-
types in these lines demonstrate their potential value as in vitro
human models, however, such phenotypes rarely correlate across
lines and some are seen as contradictory. Existing HD iPSC
lines may not faithfully represent the molecular perturbations
of late-onset HD since they potentially exhibit unknown conse-
quences by the reprogramming somatic cells exposed to mutant
HTT proteins for considerable durations, and hence PGD isolated
hESCs described in this study provide a more “natural” cellular
alternative.
Late-onset HD alleles appear to provide a unique system to
probe pre-onset changes at the molecular level and within a neu-
rological context, as attested by observations of elevated Ca2+
glutamate responses. Understanding pre-onset HD alterations
could elucidate the hierarchical relationship between various HD
hallmarks, yet is presently restricted primarily to non-invasive
imaging methodologies (Tabrizi et al., 2009; Nopoulos et al.,
2011) and peripheral blood analysis (Borovecki et al., 2005;
Runne et al., 2007; Bjorkqvist et al., 2008). The application of
late-onset hESC to long-term in vitro neuronal cultures or cel-
lular challenges that mimic in vivo conditions (i.e., oxidative or
proteasomal stressors) may provide a system to delineate the
thresholds that mark clinical onset that is otherwise difficult in
extreme CAG repeat variants. Nevertheless, future work must
simultaneously evaluate differing model systems to identify those
which most faithfully recapitulate human HD, to steer prospec-
tive in vitro therapeutic activity toward models with the highest
potential.
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